Discover how trastuzumab emtansine (T-DM1), a next-generation HER2-targeted antibody–drug conjugate, delivers precision cytotoxic therapy in HER2-positive breast cancer, improves progression-free and overall survival, and reduces off-target toxicity compared with conventional chemotherapy.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs